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1. Pathologically Unique: Pushing Towards Personalized and Holistic 
Treatment of Bipolar Disorder 
Bipolar disorder is a debilitating and chronic mood disorder characterized by the recurrence 
of depressive and manic or hypomanic episodes. These ‘mood swings’, as they tend to be defined 
in popular media, are not just periods of erratic behavior and impulsiveness. For the person living 
with bipolar disorders, these constant fluctuations in mood affect their ability to function in an 
everyday setting. Work performance, relationships with friends and family, financial stability - all 
of these factors can be negatively impacted by bipolar disorder. Bipolar disorder requires a huge 
utilization of resources and frequent hospitalizations, which are particularly necessary in managing 
manic episodes (Squassina, Manchia, and Del Zompo, 2010). Financially, bipolar disorder has an annual 
cost of approximately $45 billion per year in the United States; $7 billion of that direct cost comes 
from expenditures for inpatient and outpatient care (Squassina et al., 2010). With a prevalence rate of 
0.8-1.2%, and increased risk of early death, disability, and suicide, bipolar disorder produces 
substantial socioeconomic and psychosocial burden worldwide (Pisanu, Heilbronner, and Squassina, 
2018).  
Currently, there is no cure for bipolar disorder, only treatment to ameliorate the symptoms. 
However, even the treatments currently used are not conclusively effective, and they each present 
with their own array of side effects. For a fair amount of people living with bipolar disorder, 
treatments are not effective at all. This begs the question: if these drug interventions are ineffective 
and dangerous, why are they still in use? Nonetheless, bipolar disorder is considered a fairly 
manageable disorder. Assuming patients receive an accurate diagnosis, the vast majority of people 
can achieve substantial stabilization of their mood and related symptoms with the proper treatment 
(Oedegaard et al., 2016). This ideal, however, relies on the patient receiving an accurate diagnosis. The 
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unfortunate truth is, for many people living with bipolar disorder, there are multiple visits to various 
specialists and several second opinions before even a semi-accurate diagnosis can be achieved. This 
process alone can have a negative impact on the patient’s well-being. Furthermore, bipolar disorder 
not only manifests itself physically, it impacts mental, emotional, and social well-being as 
well.  Due to its high morbidity, disability, and premature mortality, bipolar disorder is a major 
health problem with severe socioeconomic implications (Squassina et al., 2010). Bipolar disorder 
negatively affects a person’s relationships, both personal and professional, and comes with higher 
financial costs. The severity of these costs, both economic and emotional, highlight the full extent 
of strife that those living with bipolar disorder experience.  
Too often the health care industry relies on broad scientific background in order to diagnose 
a patient. While this foundational knowledge is key, doctors and health care professionals would 
do well to apply their knowledge to each individual patient. Extensive and detailed information 
should be collected before a patient receives treatment, such as the patient’s symptoms or their 
family history. By establishing this level of detail, doctors will have greater understanding of the 
patient’s needs, and provide them with better treatment. A movement towards personalized 
medicine needs to be pursued, especially in the field of mental health. Treating the patient rather 
than their symptoms can yield more accurate diagnoses, efficient treatment, and improved quality 
of life.  
1.1   Bipolar Disorder: The Structural and Biochemical Basis  
 Bipolar disorder can be considered a spectrum disorder, with pathology and symptoms 
presenting uniquely across patients. For clinical purposes, however, there are clearly defined 
classifications. Bipolar disorder is broken down into type I  and type II . Those living with type I 
suffer from recurrent manic episodes, often accompanied by an inflated sense of self-esteem, 
increased talkativeness, racing thoughts, and increased goal-directed activity (Bear, Connars, and 
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Paradiso, 2016). . Manic periods can last for months, and onset is not easily predicted. Conversely, 
patients with type II present with depression-like symptoms. Patients suffer from hypomania, a 
milder form of mania that is not associated with marked impairments in judgements or 
performance, but with greater episodes of major depression (Bear et al., 2016). Type I occurs in about 
1% of the population, equally across men and women, and type II occurs in about 0.6% of the 
population (Bear et al., 2016), which appears to be more common in women.  
The deterioration of several brain regions and structures have been implicated in the 
development of bipolar disorder. Bipolar disorder is characterized by neurotrophic alterations 
resulting in impaired signaling and neuroplasticity with a significant overall reduction in cortical 
volume (Squassina et al., 2010). This decreased volume can be found throughout the cortex, though 
there are a few key regions consistent with bipolar disorder behavior. For example, frontal lobe 
abnormalities are often seen with bipolar disorder and are consistent with observed deficits in 
executive functioning (Abe et al., 2015). Specific brain volumetric alterations such as enlargement of 
the ventricles, reduced grey matter in the orbital and medial prefrontal cortex, and reduced volume 
in the frontal lobe and hippocampus could correspond to reduced neuronal size and density 
(Squassina et al., 2010). These brain regions are associated with proper executive cognitive functioning, 
suggesting that cortical reduction to this area contributes to the impulsive, erratic behavior 
characteristic of manic episodes. 
What remains unclear is whether damage to the brain produces the bipolar behavior, or if 
the physical decline is due to the progression of the disorder. Reduced grey matter may be the cause 
of bipolar disorder - or, it might be a byproduct. The extent of cognitive functioning impairment is 
correlated with the number of manic episodes a patient experiences (Abe et al., 2015). Patients can 
show significant cortical volume decrease in frontal regions after just one manic episode. This 
finding helps to illustrate how rapidly damaging manic episodes can be, challenging the notion that 
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damaged structure precedes altered behavior. Furthermore, no significant change in cortical volume 
has been seen in patients who did not experience a manic episode. Patients did present with a 
decrease in cortical surface area. However, the effects of this decrease may be mitigated by an 
increase in cortical thickness, resulting in an overall unaltered cortical volume. Cortical 
deterioration may be exacerbated by recurrent manic episodes, and the combination produces the 
overall behavior characteristic of bipolar disorder. This relationship between anatomy and 
physiology requires further exploration.  
As of yet, no neurotransmitter system has been concretely tied to the etiology and 
pathology of bipolar disorder. The interaction of several neurotransmitter systems might contribute 
to susceptibility to the disease (Shi et al., 2008). Much of the research into neurotransmission comes 
from looking into possible genetic variants in each neurotransmitter system, highlighting the 
potential insights genetic testing could provide. Dopaminergic dysfunction could contribute to the 
etiology of mood disorders; but evidence of stress-induced GABAergic functional changes exists 
as well (Shi et al., 2008).  A variant of the tryptophan hydroxylase 1 gene, which catalyzes the rate 
limiting step of serotonin synthesis, may be connected as well (Pisanu et al., 2018). In recent years, 
data has pointed to a glutamatergic explanation of bipolar disorder. Glutamate functions in 
excitotoxicity, a process where over-stimulation of neurons due to increased intracellular calcium 
levels leads to cellular death. This excitotoxicity could lead to an increase in the synthesis of 
reactive species, promoting inflammation and causing the tissue damage characteristic of bipolar 
disorder (Data-Franco et al., 2017). The glutamatergic hypothesis is promising, though more research 
should be performed. Some currently propose that an imbalance between the main excitatory 
neurotransmitter, glutamate, and the main inhibitory neurotransmitter, GABA, could be at play in 
the physiology of the disorder (Data-Franco et al., 2017). The imbalance between these two 
neurotransmitters could contribute to the alternating manic-depressive periods of bipolar disorder. 
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Raised levels of glutamate have been found in the frontal cortex of bipolar patients (Data-Franco et 
al., 2017). Abnormal expression of several subunits for NMDA, AMPA, kainate, and metabotropic 
glutamate receptors have also been discovered in regions relevant to bipolar disorder, such as the 
hippocampus and the frontal cortex (Data-Franco et al., 2017). Exploring the role of glutamate synthesis 
and neurotransmission may be of great importance in determining bipolar disorder etiology and 
pathology. Future research would do well to explore all the possible genetic variants related to 
glutamatergic synthesis, and neurotransmission in order to conclusively address the underpinnings 
of bipolar disorder.  
The inositol 1,4,5-triphosphate / calcium (InsP3 / Ca2+) signaling pathway is responsible for 
generating Ca2+ signals throughout the body. It is well known that Ca2+ signaling plays a role in 
countless processes such as metabolism, cell proliferation, smooth muscle contraction, and memory 
formation in neurons. In the InsP3 / Ca2+ pathway, phospholipase C receptors are activated and InsP3 
and diacylglycerol are produced. These products act as intracellular signals that trigger calcium 
release and activate protein kinase C. Inositol monophosphatase (IMPase) and inositol 
polyphosphatase (IPPase) then enzymatically dephosphorylate the inositol products into free 
inositol, which can be recycled to the membrane. Bipolar disorder may arise as a result of an 
overactive inositol signaling pathway (Berridge, 2016). Data has shown that key components of this 
pathway are present in the occipital cortex of patients with bipolar disorder. Furthermore, 
stimulating inositol 1,4,5-triphosphate or ryanodine Ca2+ receptors creates a depressive state in 
mice; when this pathway is inhibited, an antidepressant like effect is observed (Galeotti, Bartalini, and 
Ghelardini, 2006). Research exists regarding the factors that may affect the activity of this pathway. 
Pharmacological research has also been conducted to see how this pathway might be biochemically 
manipulated. The InsP3 / Ca2+ signaling pathway may represent the most solid hypothesis that exists 
regarding bipolar disorder, and it should continue to be explored.  
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1.2   The Missing Genetic Link 
 In recent years, research has searched for genetic variants implicated in bipolar disorder. 
Assessing the role of genetic polymorphisms in bipolar disorder is informative because it opens 
doors regarding personalized treatment, and may hint at possible preventative measures. Twin and 
adoption studies are characterized by high heritability, suggesting genes exert a high-magnitude 
effect on the development of bipolar disorder (Squassina et al., 2010). Genetic variation could affect 
how well patients respond to treatment and drug intervention. Common genetic variation accounts 
for up to 42% of variance in antidepressant response (Perez et al., 2017). The theory of genetic 
mosaicism may explain why  bipolar disorder symptoms appear on a spectrum. One person’s 
symptoms will not be identical to another, so logically, their treatment plans should not be identical 
either. Introduction of personalized medical approaches would account for patient variables, such 
as genetic history, and provide patients with more holistic and effective care.  
 Neurological disorders arise and progress due to interactions between genetics, 
environmental factors, and patient histories. No single factor operates in isolation. Understanding 
the interconnectedness is crucial, but understanding each factor completely is foundational. 
Therefore, the current aim of this investigation is to explore the effect of genetics on the 
development and treatment of bipolar disorder. Genetic variance is undoubtedly at play in bipolar 
disorder, but specific loci, mechanisms, and effects have yet to be concretely determined. Genetic 
testing will be essential in providing answers, and may lead to improved treatment plans for 
patients.  
 Pharmacogenomics is a novel approach to genetic testing that analyzes how genetic 
variants modulate patient response to drug intervention. Testing considers both pharmacokinetics 
and pharmacodynamics. Pharmacokinetics encompasses drug metabolism and transport, 
specifically focusing on how hepatic biotransformation impacts the drug concentration to drug 
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effect relationship (Lombard and Doraiswamy, 2013).  Pharmacodynamics studies the drug’s effect on 
receptors, transporters, enzymes, and second messengers. Effects are examined in both the brain 
and in non-specific tissues, allowing clinicians to determine their efficacy for producing the desired 
treatment effect (Lombard and Doraiswamy, 2013). Pharmacogenomics could provide a method of 
reducing heterogeneity of diagnoses and treatment, and by extent, highlight the biological 
underpinnings of bipolar disorder. The integration of pharmacogenomic techniques and practice 
with individual treatment represents a powerful instrument for the development of personalized 
therapies (Squassina et al., 2010).  Implementation of genetic testing across mental health could move 
current knowledge ahead of where it currently stands. Genetic approaches to mental illness 
diagnoses and treatment could identify clinically significant predictors of efficacy and possible side 
effects caused by psychiatric medications (Dubovsky and Dubovsky, 2015). Theoretically, by 
establishing a genetic profile for any given patient, clinicians could use a more targeted treatment 
approach right away, and avoid the barrage of side effects that is inherent to trial-and-error 
treatment. Mental healthcare needs a shift in perspective. Clinicians are not just tackling a disorder 
by battling the symptoms - they are treating a patient, whose needs should extend beyond their 
immediate condition. Starting a movement towards personalized medicine, by way of 
pharmacogenomic testing, could provide patients with the more holistic and efficient treatment that 
is right for them, and perhaps lead to profound scientific discovery in the process.  
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2. Band-Aid Solutions: Inefficacy and Inefficiency in Bipolar Disorder 
Treatment  
2.1 .  Current Treatments 
While medicine and pharmaceutical interventions have come a long way, treatment for 
bipolar disorder has yet to be perfected.  Advances in pharmacological treatment exist. However, 
patient response and remission rates for current antidepressants remain nonoptimal, emphasizing 
the need for improved utilization of current therapeutic tools (Perez et al., 2017). In current practice, 
lithium remains the standard  against which other medications are compared (Oedegaard et al., 2016). 
Modern research continues to investigate if antipsychotics or anticonvulsants have use as bipolar 
disorder treatments. These agents include valproic acid (VPA), lamotrigine (LTG), and 
carbamazepine (CBZ). Some research exists regarding the brain regions these medications may 
interact with, but specific mechanisms have not been discovered. Despite lithium’s popularity 
amongst clinicians, it is not well understood biochemically. In fact, many patients do not respond 
well to the inherent side effects. Pharmaceutical sciences have vital contributions to creating the 
medicines that we use today. Most remain useful and effective, but how they work remains a 
mystery. Furthermore, if there are still people who are unresponsive to current medical 
interventions, then more research and work needs to be done. 
Lithium is the most heavily prescribed treatment for patients with bipolar disorder. Lithium 
can reduce the frequency of manic episode recurrence by at least 30% (Squassina et al., 2010); however, 
30-40% of patients fail to respond to lithium treatment, or cannot endure sustained treatment due 
to intolerable side effects such as weight gain, acne, thyroid suppression, and gastrointestinal-
related issues. Because success with lithium seems to vary from patient to patient, it is likely that 
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good lithium responders constitute a clinically and genetically distinct group (Oedegaard et al., 2016). 
In fact, several studies in recent years have worked to demonstrate the existence of lithium-
mediated gene expression changes. One such study documented changes in the expression of 
various genes in response to lithium treatment, including those involved in signal transduction 
pathways (Oedegaard et al., 2016). A link seems to exist between certain genes and lithium response, 
yet there is still inconsistent treatment success across patients. Further genetic testing could be 
beneficial in developing a method to predict individual response to lithium treatment. Not only 
would this genetic information be of great benefit to clinicians in making prescriptions, but it may 
also accelerate the patient’s recovery and reduce their financial costs (Oedegaard et al., 2016). Genetic 
testing could provide better foresight, and shine light on the best treatment needed to fit the patient’s 
needs.  
Alternatives to lithium including different classes of antipsychotics and anticonvulsants, 
have been explored in recent years. Much of the focus concerns valproic acid (VPA), lamotrigine 
(LTG), and carbamazepine (CBZ). Among anticonvulsants, VPA, LTG, and CBZ have strong 
evidence-based support for use in clinical states of bipolar disorder, and data has also supported 
their roles as potential long-term treatments to prevent relapse (Squassina et al., 2010). VPA yields the 
most effective treatment in mania, at least for a particular subgroup of bipolar disorder. Good 
responders to VPA are characterized by: the presence of pure, mixed, or dysphoric mania; early 
age of onset; rapid cycling; concurrent substance abuse; and a lack of response or intolerance to 
lithium (Oedegaard et al., 2016). LTG is effective for patients with earlier onset of symptoms, 
nonepisodic course of the illness, comorbidity with panic disorders, fewer hospitalizations, fewer 
prior medications, and especially is effective in males (Oedegaard et al., 2016). Less seems to be known 
regarding CBZ’s applications, but successful treatment seems to be predicted by more clinical 
features, such as mood-incongruent psychosis, lack of response, or intolerance to lithium (Oedegaard 
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et al., 2016). These medications all find success with a very specific subgroup of bipolar disorder, 
and are often used for patients whose initial treatment with lithium was ineffective. The need for 
these alternate drug options reinforces lithium’s lack of universality. Furthermore, it emphasizes 
the likeliness of a patient variable. Lithium, VPA, LTG, and CBZ all have viable treatment 
applications, but are only effective for a particular subset of patients with bipolar disorder. If more 
was known about the patient’s history, genetic background, and specific symptoms, clinicians 
would not have to follow down the list of possible drug interventions. They would know which 
drug to administer right away, and the patient could have a more personalized, more effective 
treatment.  
2.2   Genetic Influences 
Though not the only etiological factor, genetic variation across patients is nonetheless a 
vital source of variability that should be thoroughly examined. Genetic polymorphisms affect both 
drug targets and drug metabolism, and therefore are important sources of individual variability in 
treatment and adverse effects (Dubovsky and Dubovsky, 2015). There are efforts to define the mechanism 
of medications in the context of these genetic polymorphisms, though their overall connection to 
bipolar disorder remains unclear. As it stands there is no single gene firmly connected to bipolar 
disorder. Research has proposed several regions that warrant further study. MicroRNA have links 
to current pharmacological treatment of bipolar disorder. MicroRNAs are short, noncoding post-
translational regulators of gene expression that have been linked to circadian clock machinery, a 
biological mechanism associated with bipolar disorder as well as major depression (Dubovsky and 
Dubovsky, 2015). MicroRNAs could be a target site for antipsychotic medications (Perez et al., 2017), 
and may be affected by lithium use. Sadly, the usefulness of microRNAs as biomarkers for bipolar 
disorder is limited by their associations with several disorders. It is hard to elucidate the true 
mechanism of microRNAs in bipolar disorder. Another protein of significant interest is GSK-3𝛽. 
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GSK-3𝛽 is a highly conserved protein involved in the regulation of apoptosis, circadian rhythms, 
and a wide range of neuronal functions and pathways associated with tissue development (Squassina 
et al., 2010). It is affected by administration of both lithium and valproate. MicroRNAs and GSK-3𝛽 
both seem to regulate similar functions, and they are both affected by current bipolar disorder 
treatments. Understanding how these genes function and how they can vary will be essential to 
understanding the true genetic variables of bipolar disorder. 
The inositol pathway is currently being investigated as a target for drug intervention. 
Research has shown that lithium directly inhibits both enzymes of the inositol pathway (Oedegaard 
et al., 2016; Squassina et al., 2010; Pisanu et al, 2018). The inositol depletion hypothesis is based on the 
observation that Li+ acts by inhibiting the inositol monophosphatase (IMPase) that hydrolyzes 
inositol monophosphatase to form free inositol, which could inhibit the inositol pathway signaling 
(Berridge, 2016; Oedegaard et al., 2016). VPA is also suggested to impact this pathway, though by 
a different action than lithium (Squassina et al., 2010). Lithium can be considered a homeostatic drug: 
it has no effect on the InsP3 / Ca2+ pathway when it is operating normally, but its therapeutic action 
becomes increasingly effective to match the degree of hyperactivity exhibited by the pathway 
(Berridge, 2016). The belief is that the effect of Lithium alters to match the severity of bipolar disorder. 
However, given that lithium does not work for every patient, there must be an exception to this 
logic. Perhaps there are genetic markers that reveal information about the activity of the InsP3 / Ca2+ 
pathway. Genetic testing could reveal genetic polymorphisms that predispose a person to abnormal 
InsP3 / Ca2+ activity, which may in turn be suggestive of bipolar disorder risk. There is consensus 
that good predictors of viable lithium response include lower inositol monophosphatase mRNA 
expression (Squassina et al., 2010). Genetic testing could help to elucidate the true connection between 
inositol signaling and bipolar disorder etiology. This may be the most promising research route 
discovered in recent years, and no doubt requires further investigation.  
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2.3   The Risk of Adverse  Drug Effects 
The fact of the matter is that most pharmaceutical treatments do not selectively interact 
with the target of interest, but bind to several different regions. This promiscuity could set off 
downstream, and sometimes adverse, reactions. Because of this, use of a single isolated treatment, 
or monotherapy, is not always effective (Oedegaard et al., 2016). In an attempt to combat this 
nonspecific binding, some physicians may choose to employ a combination of treatments. 
However, by increasing the chance of successful binding to the desired target, the risk of adverse 
chain reactions also increases. Exposing patients with a barrage of drugs likely will not increase 
the efficacy of the treatment. Knowing which medicine is best for each patient can be discovered 
with genetic testing, and will ensure the patient receives more holistic and effective care.  
Though drug intervention can mitigate the effects of bipolar disorder, patients can still 
experience symptoms. Sometimes the side effects of medication only cause more issues. A 
prominent concern is neurocognitive deficits brought on by certain medications. In fact, cognitive 
slowing is not an uncommon side effect for many of the currently used mood stabilizers (Oedegaard 
et al., 2016). Though not a desired outcome, it can be difficult for doctors and pharmacologists to 
tackle one aspect of a disorder without causing some downstream adverse effects. Measures such 
as genetic testing would enable physicians to determine if there are physical markers for side 
effects, such as the neurocognitive deficiencies, or even a risk of relapse, and see if they are 
associated with a specific gene (Oedegaard et al., 2016).  
However, the problems bipolar disorder and drug intervention create are not always 
physical. Besides failure with first- or second-line therapy, disability and economic costs associated 
with bipolar disorder are linked to high rates of drug-induced adverse effects (Perez et al., 2017). With 
time adverse effects can impair a patient’s emotional, mental, and financial well-being.  What does 
it say about modern medicine if the desire to target a particular symptom is weighed more heavily 
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than the patient’s individual needs? Consciously, people might agree that treatment needs to be 
more holistic - but is that actually being achieved? The reality is that bipolar disorder is a major 
cause of hospitalizations and healthcare expenditures (Squassina et al., 2010). In some cases, bipolar 
disorder can even lead to suicide (Oedegaard et al., 2016; Pisanu et al., 2018). These are not easy things to 
think about.  It can be easier to focus on the ‘science’ of the disorder, rather than the more personal 
aspects. But from these facts alone, it can be presumed that the mental health and emotional well-
being of bipolar patients is not being adequately addressed.  
The financial toll treatment takes on patients is not given proper attention either. Lithium 
still remains the drug of choice among clinicians, despite inevitable side effects. Other medications 
such as VPA, LTG, and CBZ have shown moderate success for different subsets of patients in the 
clinical setting. However, the cost of treatment with these newer agents is in excess of 10 times 
higher than that of lithium; for example, it can cost $60 per month for valproic acid, while it may 
cost as little as $1 a month for lithium treatment (Oedegaard et al., 2016). This large difference in price 
creates a dilemma for patients. Do they use lithium because of its low financial cost, regardless of 
the side effects they may experience? Or do they take the chance with valproic acid? It may prove 
to be more effective for them, but it does present a big economic gamble. If only patients had a way 
of knowing which drug would be the most effective for their needs.  
 Adverse drug effects are often the result of complex factors that are several steps removed 
from simple biochemical pathways, such as metabolism. At this level the drug’s efficacy, or lack 
thereof, is more likely determined by the patient’s genetics than the drug’s design. There is a strong 
relationship between economic burden and genetic variation as it related to treatment for 
schizophrenia (Herbild, Andersen, Werge, Rasmussen, and Jurgens, 2013). Four functionally distinct groups 
of metabolizers exist, classified by the number of functional copies of each CYP gene they had 
present. Patients classified as hyper metabolizers or as poor metabolizers incur substantially higher 
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costs than similar patients with a more moderate metabolizing genotype. Because these groups of 
people have a more extreme, inconsistent metabolism, it is difficult for physicians for doctors to 
discern the best treatment route. Too much time gets spent trying to find the proper dosage. This 
process not only racks up financial costs, but negatively impacts the patient both emotionally and 
physically. However, there is a solution that could account for this patient variability and transition 
towards more effective, personalized care.  
2.4   The Advent of Pharmacogenomic Testing 
Pharmacogenomic testing could be used as a preemptive measure to screen patients and 
provide precise and personalized treatment (Herbild et al., 2013). In essence, pharmacogenomic testing 
would create a genetic profile of sorts that would allow physicians to see which genetic 
polymorphism are present. They could then see which polymorphisms are associated with a 
disorder and target that specific mutation. This method of testing could be extremely useful in the 
diagnosis and treatment of poor metabolizers and hyper metabolizers. Identifying these patients 
and taking their baseline metabolic capacity into account when prescribing medication is suggested 
to reduce the adverse effects associated with frequent changes in pharmacological treatment (Herbild 
et al., 2013). Pharmacogenomic testing would not only establish a more accurate and effective 
treatment option for patients, but it would decrease the time, cost, and energy that is usually devoted 
to a ‘trial and error’ treatment route.  
Some remain unconvinced. If a certain gene is genuinely connected to a drug’s action, 
irrefutable evidence must show that the relationship is caused by the drug administration and not 
by the natural pathology of the disorder. For example, can it be proven that a single nucleotide 
polymorphism (SNP) is associated to lithium response and not to some other biochemical process 
unrelated to the drug’s administration (Oedegaard et al., 2016)? If the drug is working, why can’t it be 
left at that? Furthermore, once in the central nervous system, the role of genetic polymorphisms 
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becomes much harder to assess than examining other biochemical processes, like the role of 
metabolizing enzymes (Dubovsky and Dubovsky, 2015).  Truthfully, it is difficult to separate out the 
exact factors determining a drug’s effectiveness, or lack thereof. Drug response and tolerability 
profiles depend on the combined effects of different genes as well as environmental and clinical 
factors (Perez et al., 2017). The significance of these external, uncontrollable variables are not 
something to be glanced over. Success with a given treatment might occur, but only because certain 
external or environmental factors were in effect. Genetic testing has potential to lead to greater 
success rates for drug intervention, but 100% efficacy may not be attained because there are still 
other factors involved.  
This thought should not negate the importance of genetic testing. Some might say it is 
enough to see the correlation between genetic makeup and effective treatment. If a patient presents 
with Gene X, then they can be prescribed Drug Y, and the ‘why’ of it doesn’t really need to be 
explored. At the macroscopic level, however, data on genetic polymorphisms is invaluable. 
Knowing a relationship exists between a gene and a medication allows researchers to investigate 
possible mechanisms of action. They can then study pharmacokinetics and pharmacodynamics, 
investigate drug inhibitors and activators, and possibly elucidate a pathway towards a cure. Genes 
can be influenced by environmental and clinical factors, and may change as a result. But having 
foundational knowledge of genetics and what a healthy patient looks like can give a roadmap to the 
genetic polymorphisms of bipolar disorder. With this degree of direction, clinicians could provide 
patients with exactly what they need. 
In an ideal world, the pathology behind every disorder would be clearly outlined, and a 
treatment could be easily developed. But the aim of mental disorder research and treatment needs 
to be refocused. Scientific pursuit can easily get wrapped up gene variants and mechanisms and 
statistical significant. Too often, the patient gets overlooked. Mental health needs to regain a 
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personalized element. Doctors are not just battling a disorder; they are treating a person. Genetic 
testing could help to bridge this gap by having doctors focus on the data pertaining to an individual 
patient. Research should continue to find the root cause of bipolar disorder. But until a cure is 
found, patient care should focus on the specific treatment and holistic care of an individual person. 
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3. Pharmacogenomics in Practice: Addressing Ethical, Administrative, 
and Legislative Concerns 
Pharmacogenomics represents an innovative approach to healthcare and patient prioritized 
treatment. The innovative utilization of genetic testing has revealed genetic variants that may 
contribute to psychiatric disorders, and has revolutionized the approaches people can take in 
disorder diagnosis and management. Genome-wide association studies represent one technology 
capable of examining many genetic variants in the genome simultaneously, without any sort of 
preliminary hypothesis (Mistry, Harrison, Smith, Escott-Price, and Zammit, 2018). The degree of data 
resulting from these kinds of studies is monumentous. Not only do genetic tests provide a wealth 
of information, they can reveal genetic connections to disorder etiology or treatment efficacy that 
were otherwise unnoticed. From promoting personalized medicine and reducing the risk of adverse 
drug effects, the potential benefits of pharmacogenomics and genetic testing are far reaching. 
However, many of these practices are not time-tested, and government and administrative policies 
lag behind the technological advancements. Pharmacogenomics makes groundbreaking and vital 
contributions to modern medicine, but its application raises several clinical, economic, and 
legislative  concerns.  
These ethical and logistical concerns must be adequately addressed for genetic testing to 
be effectively implemented in healthcare policies. Not having clear guidelines and policies in place 
before the technology becomes standard clinical practice may have detrimental economic, ethical, 
and operational effects, and may also give health care providers, consumers, and service providers 
free reign in the procurement and use of testing (Bashir an Ungar, 2015). Ambiguity is not beneficial 
to clinicians or to patients. For pharmacogenomic testing to be beneficial and effective, there must 
be guidelines, procedures, and even laws in place. Knowing who will be providing and financing 
services, who should be able to requisition the technology, and how the information will be used 
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must be clear at both the federal and local level (Bashir an Ungar, 2015). Pharmacogenomic testing can 
improve mental health diagnosis and treatment. But it must be proven that the costs of 
implementing genetic testing practices and policies will not outweigh the benefits of the data.  
3.1   The Patient Perspective 
Often in health care, the clinical voice becomes the loudest. The focus is on tackling 
symptoms the best clinicians can with the treatments and procedures they have available to use. 
Patient voices can then be overshadowed, and their wellbeing can be overlooked. Even though 
clinicians have the scientific expertise and training, patients have a right to be an active part of their 
health care. Patients deserve ample knowledge about their health care options in order to make 
informed decisions. As genetic testing advances, patients should have access to information and 
resources pertaining to pharmacogenomics. Because little information is offered, patients have 
limited understanding regarding genetic testing. In theory patients welcome the benefits of 
pharmacogenomic testing for improved diagnosis and care; but, they have concerns about the 
emotional burden of genetic results, the value of testing, and whether testing could be used to ration 
care (Bashir an Ungar, 2015). Patients need to be convinced that the ordeal of genetic testing will be 
beneficial to their overall health, and not bring about any more pain or problems.  The patient 
perspective is too easily overlooked in mental health care, and it is time their concerns were 
properly addressed.  
Privacy is a prominent concern when it comes to personal information. Genetic testing can 
be invasive, and not knowing who can access results gives patients anxiety. A considerable issue 
with genetic testing is the practice of genetic discrimination. Genetic discrimination occurs when 
people are treated differently due to their genetic makeup, with some definitions specifying that 
discrimination would occur as a direct result of the genetic testing (Bashir an Ungar, 2015). The patient 
concern is that their genetic background will be unfairly used by insurance providers or employers 
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to determine coverage or employment. Though perhaps unlikely, this is a concern that required 
further thought. Many states have passed laws to address these concerns, and there have been 
attempts to pass federal legislation banning the use of genetic risk information in health insurance 
underwriting (Garrison et al., 2008). Some have argued that these kinds of laws infringe on the rights 
of private business, such as insurance companies, because it forces some to assume the risks of 
others. While the spirit of the law is to protect people, the true logistics implications require further 
consideration.  
Pharmacogenomic testing can be instrumental in giving patients accurate diagnoses and 
effective treatment. It has the power to reduce financial costs of care, and reduce the patient’s risk 
to adverse side effects. While this information is invaluable, people often fail to consider the 
emotional stress genetic testing can create. Patients can feel empowered to take a proactive stance 
in their health care by requesting pharmacogenomic tests; but, they are often ill equipped from a 
knowledge and emotional standpoint to handle their results (Bashir an Ungar, 
2015).  Pharmacogenomic testing can establish genetic profiles and reveal regions of interest. If a 
patient is told they have a genetic risk variant for bipolar disorder, are they given resources on how 
to go forward? Are clinicians and genetic testing services required to give the patient a referral for 
treatment? With no sort of system or procedure in place, patients are left to flounder and seek out 
medical advice for themselves. The wealth of information pharmacogenomic testing can provide is 
useless if patients and clinicians do not know how to respond to it. Patients deserve to move through 
the health care system more smoothly. They should have the right to informed clinicians and ample 
resources so that they can receive effective, compassionate, and holistic care.  
3.2   Clinical Concerns 
Pharmacogenomic testing is understandably not well-known amongst the general 
population. But surprisingly, it remains novel in the clinical setting as well. According to a 2008 
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National Survey, only 10% of physicians nationwide feel that they have adequate understanding of 
pharmacogenomic tests, even though 98% believe pharmacogenomic testing would benefit their 
patients (Heale, Khalifa, Stone, Nelson, and Del Fiol, 2017). Theoretical knowledge alone is not enough if 
clinicians do not even have the training to utilize genetic testing properly. Clinicians often adopt a 
‘berry-picking’ information-seeking model, in which they ‘pick’ information from different 
locations that is relevant to their inquiries. This strategy can hinder both the physician and the 
patient. The clinician gets an incomplete understanding of a given testing procedure, and will not 
know when or how to use it properly. The patient misses out on holistic treatment because they are 
not presented with a thorough list of options. The physician and patient relationship needs to be 
more balanced, and therefore both parties should have resources to be knowledgeable about the 
methods and interpretations of pharmacogenomic testing.  
 What is the best way for clinicians to stay up to date on pharmacogenomic knowledge and 
practices? Some have suggested that a pharmacogenomic database may prove quite useful. A 
platform of this kind would allow doctors to seek out genetic testing information in a user-friendly 
yet comprehensive way. They would have access to a plethora of resources, but navigate it with 
their particular focus in mind. Additionally, structured search forms could help guide clinicians 
through the search process by employing a PICO- based search model (Population, Intervention, 
Comparison, and Outcome) (Heale et al., 2017). With this type of clear cut and efficient system 
clinicians could focus their investigations specifically to the needs of their patient. More so, in 
researching for a specific genetic variant or pharmacogenomic test, a database could guide 
clinicians to alternate routes of investigation - perhaps refining their searches and given both 
clinician and patient a more holistic understanding of the treatment options. Another approach to 
assisting clinical searches involves integrating online resources with patient information in an 
electronic health record (EHR) system. This kind of system could reduce necessary navigation 
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efforts and decrease the physician’s short-term memory overload (Heale et al., 2017). Moreover, it 
would put the pharmacogenomic information directly in context with the patient’s symptoms and 
history, likely letting clinicians see a treatment path more clearly. 
Direct-to-consumer companies are an alternative to traditional health care and genetic 
testing. They allow individuals to have greater autonomy in their health care. The direct-to-
consumer pharmacogenomic testing gives the patient the ability to become more proactive in their 
health care decisions, an idea that is increasingly popular in current health care systems (Bashir an 
Ungar, 2015). These companies can provide easily accessible and quick results, and are a good 
resource to patients in their health care journeys. However, there are certain considerations patients 
should have when entrusting their genetic information to a private cooperation. Direct-to-consumer 
testing may be difficult to regulate in terms of quality care, and may create an increased demand 
for follow up health care resources (Bashir an Ungar, 2015). Because it functions as a private company, 
their genetic testing practices will likely be unaffected by any state or federal regulations. Patients 
might not be assured that they are receiving accurate or adequate information, and may not even 
have a guarantee to their privacy. Furthermore, direct-to-consumer companies may not have an 
obligation to act on the results of genetic testing. Patients may desire to respond to their results and 
seek out additional consults, but their demand for appropriate medical treatment may not be 
financially possible. These hypotheticals do highlight the concern regarding who should be allowed 
to perform genetic testing, and whether or not restrictions should be imposed (Bashir an Ungar, 2015). 
This very question is the center of debate for many administrative and legislative measures 
3.3   Legislative Logistics 
In order for pharmacogenomic testing to be effectively implemented throughout health 
care, structure, guidelines, and policies need to be in place.  Genetic exceptionalism is the view that 
genetic information is fundamentally different from other kinds of medical information, and as a 
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result, deserves special protection, regulation, and legislation (Garrison et al., 2008).  Genetic history 
is sensitive and private information, and needs to be considered with gravity.  
Four characteristics of genetic testing are frequently cited when arguing for exceptional 
treatment. Genetic information is (1) predictive of future health, (2) permanent and unchangeable, 
(3) uniquely identifying, and (4) informative about the health of family and community members 
(Garrison et al., 2008). Genetic profiles can be used to predict a person’s health and their risk for 
different disorders. But, the same can be said for cholesterol and blood glucose levels. These factors 
are indicative of disorders such as heart disease and diabetes, and are often considered in medical 
evaluations. Some would argue that just like insurance providers are allowed to test blood pressure, 
they should be allowed to request genetic profiles. Being predictive of future health alone is not a 
good justification for genetic exceptionalism. However, genes are indeed permanent and 
unchangeable. No one is capable of altering their genetic profile, and where science currently 
stands, there are no means of stopping genetic polymorphisms before they manifest. But what is 
there to stop insurance companies from labeling a genetic risk as a preexisting condition? While 
some diseases are brought on by environment and lifestyles, genetic profiles cannot be altered or 
avoided. Genetic information is uniquely identifying, creating concern regarding privacy. 
Similarly, genetic information can be extrapolated to a person’s immediate family. Many people 
do not like the idea of genetic information being traced back to them. Furthermore, while one person 
may give consent for genetic evaluation, what is to prevent that information from being connected 
to other parties? These factors lays the foundation of the argument supporting genetic 
exceptionalism. Whether or not these arguments give justification for genetic exceptionalism in 
health care administration,  legislation, and regulation will be decided through debate and policy 
creation. But the significance of these factors should not be ignored and do call for careful 
evaluation.  
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Actualizing the benefits of pharmacogenomic testing requires dedicated efforts, but it is 
not without its challenges. All of these concerns, brought forth by both clinicians and patients, can 
be addressed through adequate policy implementation in places where they currently do not exist, 
at all appropriate levels of government (Bashir an Ungar, 2015).  All levels of mental health care would 
benefit from a structured system. Clinicians would benefit from guidance and established policy on 
how to utilize genetic testing with the most effective and efficient methods. Patients would benefit 
from clear and enforced legislation regarding the use of genetic information. Legislation and policy 
creation would give structure to pharmacogenomic testing, and allow it to operate at its most 
effective capacity. However, the matter of private business shines a new light on policy creation. 
Often, private business, such as private insurance companies, are not regulated by federal and state 
law. Pharmacogenomic testing in the private sector presents another element to consider. 
Just as the clinical perspective should shift towards a patient-oriented model, insurance 
companies might become more patient oriented as well. Private insurance companies claim they 
are concerned with providing high quality products, profits, and sustainability (Bashir an Ungar, 2015). 
They aim to provide their patients with quality service; but, in reality, they function as a business 
and have their own business model and interests to maintain. For this reason, many people are 
concerned regarding insurance companies’ intentions when evaluating genetic risk. Patients and 
health care providers support laws prohibiting genetic discrimination, but insurance providers may 
challenge these laws if they prove to be detrimental to their sustainability (Bashir an Ungar, 2015). 
Insurance functions by evaluating a person’s history and current situations, judging their risk for a 
multitude of accidents and diseases, and providing corresponding coverage. But genetic risk is not 
something a person can combat. It can’t always be resolved with diet and exercise. Do insurance 
companies have a right to deny coverage based on conditions the individual has no control over? 
For private insurers, until genetic discrimination laws are in place, they are free to include a 
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patient’s genetic information in their calculation of risk and coverage level (Bashir an Ungar, 2015). 
Whether this should be considered legal or not remains to be decided, but it does highlight the 
necessity of legislative investigation and policy creation.  
Obviously, the overall benefit of pharmacogenomic testing is the heart of any legislative 
initiations. Does the good outweigh the harm? Pharmacogenomic testing is a novel and ground-
breaking tool from a scientific and clinical perspective. But do the ethical, regulatory, and 
legislative concerns contradict its usefulness? Does the cost of creating policy outweigh the good 
that may come from the practice? While costly adverse events may be averted with 
pharmacogenomic testing, the costs of policy reform, service coordination, delivery, health 
technology assessments, and training resources may offset any true cost savings (Bashir an Ungar, 
2015). There are several practical and logistical points to address in any conversation regarding 
pharmacogenomic testing. Pharmacogenomics undoubtedly would excel mental health care. It 
would decrease the time, energy and money spent trying out diagnoses before the right one is 
named. It would ensure patients no longer have to play trial-and-error treatment games, and could 
get the solution designed for their needs sooner. Legislative and policy debates must weigh the 
good of pharmacogenomic testing with the cost and logistics of policy implementation, and decide 
if it is ultimately worth the effort.  
3.4   The Power of Pharmacogenomic Testing 
 Pharmacogenomic testing provides undisputed benefit to both scientific research and 
clinical practice. While public policy may waffle over the cost of policy creation, the benefits of 
genetic testing cannot be denied. As discussed earlier, there are several studies showing genetic 
testing leads to reduced treatment costs. Additionally, research has shown a correlation between 
pharmacogenomic testing and a decrease in adverse drug effects. Pharmacogenomic testing 
provides invaluable data by revealing genetic variants of interest that deserve further study. This 
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kind of evidence may even lead towards preventative measures for bipolar disorder - it may even 
be instrumental in the development of a cure.  
 As previously stated,  there is a strong correlation between pharmacogenomic testing and 
reducing cost to the patient (Herbild et al., 2013). Treatment costs tend to be considerably higher for 
people with more extreme, unregulated metabolism. However, pharmacogenomic testing allowed 
researchers to identify this group of extreme metabolizers and direct their treatment accordingly. 
From this research, it can be shown that pharmacogenomic testing not only reduces excess cost of 
care or drug intervention, but also decreases the patient’s risk for adverse drug effects. Clearly, 
genetic testing has financial benefit. What policy makers worry about is whether the cost of savings 
outweighs the cost of genetic testing itself. However, if procedures were designed to be simple and 
efficient, then this worry wouldn’t need to exist. Though some may doubt the usefulness of genetic 
testing, easy methods of obtaining relevant DNA samples through blood or saliva would decrease 
the cost of genotyping, and could make genotyping a routine component of medical care (Dubovsky 
and Dubovsky, 2015). Cost effective pharmacogenomic practices exist. It just requires efforts on part 
of policy makers and health care administration to make them a reality. 
 Considerably the most compelling benefit of pharmacogenomic testing is the reduction of 
adverse drug effect risk. In Canada roughly 3600 hospital deaths occur annually as a result of 
adverse drug effects. Furthermore, adverse drug effects were found to prolong hospital stay by an 
average of 4.6 days and increase hospital costs by $300 million per year (Bashir an Ungar, 2015). 
Fortunately, genetic testing can be used to account for adverse drug effects, and possibly reduce 
the prevalence rate. This fact alone speaks to the significance of pharmacogenomic testing. Patients 
can be provided with more personalized, holistic medicine and have more effective and efficient 
treatments. This is the goal of genetic testing. This is what should be driving policy and practice 
creation.  
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 From a larger perspective, pharmacogenomics also has applications in pharmacology. 
Genetic variants revealed by  genetic testing can be used to create better drug design and delivery 
methods. Pharmacogenomic testing information could allow for smaller, shorter, faster, and 
cheaper drug trials with improved success rates (Garrison et al., 2008).  Genetic information could be 
used to identify the different subtypes of a given disorder, which would let drug designers create 
more targeted medications. Additionally, an understanding of the relationship between a genetic 
marker and drug efficacy could enable the design of a clinical trial that is enriched with likely 
responders (Garrison et al., 2008). By knowing which gene a medication might interact with, or 
knowing which specific symptoms a drug best combats, drug trials will be made more efficient. 
Genetic research could bring science close to the discovery of a key genetic polymorphism, 
possibly pointing researchers towards a more directed search for a cure.  
 Ultimately, the benefits of pharmacogenomic testing cannot be denied. Efforts to create 
legislation and administrative practices are difficult. There are indeed many ethical and systematic 
concerns to address. But pharmacogenomics has so many widespread applications. It is proven to 
be beneficial from both a clinical and patient perspective. Genetic testing is known to decrease the 
risk of adverse drug effects. It is also proven to reduce cost to both the clinician and the patient. 
Furthermore, pharmacogenomic testing can provide scientific clarity. It provides the possibility of 
uncovering key genetic variants related to bipolar disorder, and may even refocus research towards 
an obtainable cure. Pharmacogenomic is a groundbreaking scientific and clinical technology, and 
therefore warrants further investigation so that it can be effectively implemented into modern health 
care practices. 
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